Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jad Chahoud"'
Autor:
Guillermo Garcia-Manero, Jad Chahoud, Naveen Pemmaraju, Jenny Dahl, Alessandra Ferrajoli, Jovitta Jacob, Farhad Ravandi, Elias Jabbour, Koji Sasaki, Rebecca Garris, Naval Daver, Maria Khouri, Hagop M. Kantarjian, Jorge E. Cortes, Tapan M. Kadia
Publikováno v:
Blood. 126:1298-1298
Background: Patients with relapsed/refractory (R/R) ALL have limited therapeutical options. Monoclonal antibodies have shown to be effective. Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 antibody conjugated to calicheamicin that has shown
Autor:
Srdan Verstovsek, Marina Konopleva, Zeev Estrov, Koichi Takahashi, Jad Chahoud, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Hagop M. Kantarjian, Jorge E. Cortes, Sherry Pierce, Musa Yilmaz, Guillermo Garcia-Manero, William G. Wierda, Nitin Jain, Koji Sasaki
Publikováno v:
Blood. 126:3722-3722
Introduction: Older age, poor performance status, diminished organ function and adverse genetic features are poor prognostic factors in treatment of ALL. Our goal is to develop prognostic models predicting complete response (CR), death in CR, 2-month
Autor:
Susan O'Brien, Deborah A. Thomas, Koji Sasaki, Guillermo Garcia-Manero, Musa Yilmaz, Hagop M. Kantarjian, Gautam Borthakur, Tapan M. Kadia, Naveen Pemmaraju, Jorge E. Cortes, Rebecca Garris, Farhad Ravandi, William G. Wierda, Jad Chahoud, Haim G. Moore, Twilla Victoria Jeanis, Elias Jabbour, Alessandra Ferrajoli
Publikováno v:
Blood. 126:2496-2496
Background: Addition of tyrosine kinase inhibitors (TKIs) to chemotherapy improves outcome in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib is a more potent BCR-ABL inhibitor, and covers the T315I clones. The co
Autor:
Heather M Schroeder, Guillermo Garcia-Manero, Marina Konopleva, Jad Chahoud, Paul Koller, Naval Daver, Farhad Ravandi, Elias Jabbour, Koji Sasaki, Rebecca Garris, Maria Khouri, Srdan Verstovsek, Nitin Jain, Deborah A. Thomas, Hagop M. Kantarjian, Jorge E. Cortes, Susan O'Brien, Tapan M. Kadia
Publikováno v:
Blood. 126:1295-1295
Background: The hyper-CVAD regimen is an effective frontline regimen for de novo adult ALL. Expression of CD20 was identified as an adverse prognostic factor, associated with a higher incidence of relapse, lower 3-year complete remission duration (CR